| 摘要: |
| 目的评估二甲双胍改善糖尿病合并慢性阻塞性肺疾病（COPD）预后的作用和治疗价值。方法回顾189例糖尿病合并COPD患者的临床资料。依据二甲双胍的使用情况将患者分为二甲双胍组97例和非二甲双胍组92例，对比两组患者的人口数据学资料、吸烟率、激素使用率、BMI分级分布、糖尿病病程、糖尿病并发症和胰岛功能，以及3年内COPD急性发作率、高乳酸血症和呼吸性酸中毒发生率，总住院率和因COPD急性发作或COPD相关呼吸系统并发症而致住院率，并进行生存分析。结果两组患者性别、年龄、吸烟率、激素使用率和BMI比较差异均无统计学意义。两组患者的糖尿病病程、糖尿病并发症和胰岛功能比较差异均无统计学意义。二甲双胍组患者COPD急性发作的发生率低于非二甲双胍组（P＜0.05）；二甲双胍组患者总住院率低于非二甲双胍组（P＜0.05），因COPD急性发作和COPD相关呼吸系统并发症而致住院率也低于非二甲双胍组（P＜0.05）。结论二甲双胍能够改善糖尿病合并COPD患者的预后。 |
| 关键词: 二甲双胍 糖尿病 慢性阻塞性肺疾病 预后 |
| DOI：10.12056/j.issn.1006-2785.2017.39.20.2017-569 |
| 分类号: |
| 基金项目: |
|
| Influence of metformin on prognosis of concomitant diabetes and COPD |
|
|
|
Wuxi Hospital Affiliated to Nanjing Medical University
|
| Abstract: |
| Objective To investigate the influence of metformin on prognosis of concomitant diabetes and chronic obstructive pulmonary disease (COPD) and its therapeutic value. Methods Clinical data of 189 patients with concomitant diabetes and COPD were retrospectively analyzed. The cases were divided into metformin group and non-metformin group according to administration of metformin. Demographic data, rate of smoking, rate of hormone administration, distribution of BMI classification, duration of diabetes, complications and function of pancreatic islet were compared. Incidence rates of COPD exacerbation, hyperlactacidemia, respiratory acidosis during a 3-year interval, total number of hospitalization and the hospitalization for COPD exacerbation and its related respiratory complications, were compared. Survival analysis was conducted in the two groups. Results Patients in the two groups showed no statistical differences in sex, age, rate of smoking, rate of hormone administration and distribution of BMI classification. Duration of diabetes, diabetes complications and function of pancreatic islet were also of no statistical difference in the two groups. Incidence rate of COPD exacerbation in metformin group
was lower than that in non-metformin group (P ＜0.05). Incidence of total hospitalization in metformin group was lower as
compared with non-metformin group (P ＜0.05). Incidence rate of hospitalization for COPD exacerbation and COPD-related respiratory complications were also lower as compared with non-metformin group (P＜0.05). Conclusion Metformin significantly improves the prognosis of patients with concomitant diabetes and COPD. |
| Key words: Metformin Diabetes Chronic obstructive pulmonary disease Prognosis |
